BioNTech (NASDAQ: BNTX) unveils $1.0B ADS buyback through 2027

Rhea-AI Filing Summary

BioNTech SE has authorized a new share repurchase program allowing the company to buy back American Depositary Shares for an aggregate amount of up to $1.0 billion. The program runs until and including May 6, 2027 and will be funded from existing cash resources.

The repurchased ADSs are expected to be used to satisfy obligations in the ordinary course of business. BioNTech describes the program as supporting capital efficiency, long-term value creation and financial flexibility as it pursues its objective to become a multi-product company by 2030.

Positive

• BioNTech authorized a substantial share repurchase program of up to $1.0 billion in ADSs, funded from existing cash, which signals balance-sheet strength and a commitment to returning capital while pursuing long-term growth.

Negative

• None.

Insights

Equity & capital allocation analyst

BioNTech authorizes a sizeable $1.0B buyback, signaling balance-sheet strength.

BioNTech has approved a share repurchase program of up to $1.0 billion in American Depositary Shares, running until May 6, 2027. The company plans to fund purchases from existing cash, indicating substantial available liquidity to return capital while continuing operations.

The company states that repurchased ADSs will be used to meet obligations in the ordinary course of business and that the program is intended to enhance capital efficiency, support long-term value creation and maintain financial flexibility. The design under Rule 10b-18 and Rule 10b5-1 provides a structured framework for executing repurchases over time.

Actual impact will depend on how much of the $1.0 billion authorization is ultimately used and at what prices. Management links this initiative to its objective of becoming a multi-product company by 2030, suggesting confidence in funding both pipeline investment and shareholder returns from its current financial position.

Key Figures

Share repurchase authorization: $1.0 billion Program end date: May 6, 2027 Funding source: Existing cash resources +1 more

4 metrics

Share repurchase authorization $1.0 billion Aggregate amount of ADSs authorized for repurchase

Program end date May 6, 2027 Final date by which ADS repurchases may be made

Funding source Existing cash resources Source of capital for the ADS repurchase program

Strategic objective year 2030 Target year to become a multi-product company

Key Terms

American Depositary Shares, share repurchase program, Rule 10b-18, Rule 10b5-1, +1 more

5 terms

American Depositary Shares financial

"may repurchase American Depositary Shares (“ADSs”), each representing one ordinary share"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

share repurchase program financial

"authorized a new share repurchase program (the “Program”), under which the Company may repurchase"

A share repurchase program is when a company buys back its own shares from the marketplace. This reduces the total number of shares available, which can increase the value of each remaining share and signal confidence in the company's prospects. For investors, it often suggests that the company believes its stock is undervalued or that it has extra cash to return to shareholders.

Rule 10b-18 regulatory

"designed to operate within the safe harbor provided by Rule 10b-18 of the Securities Exchange Act"

Rule 10b-18 is a regulation that sets strict rules for how a company's executives and employees can buy back their own company's stock from the market. It helps ensure that these buybacks happen in a fair and transparent way, reducing the chance of market manipulation. This is important for investors because it offers protection against unfair practices and promotes confidence in the integrity of the stock market.

Rule 10b5-1 regulatory

"and the affirmative defense provided by Rule 10b5-1 of the Exchange Act"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

forward-looking statements regulatory

"This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF MAY 2026

COMMISSION FILE NUMBER 001-39081

BioNTech SE
(Translation of registrant’s name into English)

An der Goldgrube 12

D-55131 Mainz

Germany

+49 6131-9084-0
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐

DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

On May 7, 2026, BioNTech SE (the “Company”) announced that it has authorized a new share repurchase program (the “Program”), under which the Company may repurchase American Depositary Shares (“ADSs”), each representing one ordinary share of the Company, for an aggregate amount of up to $1.0 billion. Repurchases under the Program may be made until and including May 6, 2027. The press release is attached as Exhibit 99.1.

SIGNATURE

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BioNTech SE

By:

/s/ Ramon Zapata-Gomez

By:

/s/ Dr. Sierk Poetting

Name: Ramon Zapata-Gomez

Name: Dr. Sierk Poetting

Title: Chief Financial Officer

Title: Chief Operating Officer

Date: May 7, 2026

EXHIBIT INDEX

Exhibit			Description of Exhibit
99.1			BioNTech Announces New ADS Repurchase Program

Exhibit 99.1

BioNTech Announces New ADS Repurchase Program

MAINZ, Germany, May 7, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that it has authorized a new share repurchase program (the “Program”), under which the Company may repurchase American Depositary Shares (“ADSs”), each representing one ordinary share of the Company, for an aggregate amount of up to $1.0 billion. Repurchases under the Program may be made until and including May 6, 2027. BioNTech’s disciplined approach to capital allocation and strong financial position enables this authorization.

BioNTech expects to use the repurchased ADSs to satisfy obligations in the ordinary course of business. The Program is designed to enhance capital efficiency, support long-term value creation and maintain financial flexibility alongside BioNTech’s objective to become a multi-product company by 2030.

The commencement, timing and total amount of ADS repurchases will depend upon market conditions and may be made in open market purchases from time to time, with a focus on price efficient repurchases to ensure prudent deployment of capital. BioNTech expects to fund the Program using its existing cash resources.

“We are confident in the Company’s long-term growth prospects, and this share repurchase program is consistent with our capital allocation strategy and our commitment to sustainable value creation for our shareholders,” said Ramón Zapata, Chief Financial Officer at BioNTech. “At the same time, our disciplined approach to capital deployment enables us to maintain the financial strength necessary to advance our innovative pipeline and aim for self-sustaining growth in the years ahead.”

The Program has been designed to operate within the safe harbor provided by Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the affirmative defense provided by Rule 10b5-1 of the Exchange Act.

About BioNTech

BioNTech is a global next generation biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases. In oncology, BioNTech is committed to transforming how cancer is treated. Its ambition is to develop innovative medicines with pan-tumor or synergistic potential to address cancer from multiple angles and across the full continuum of the disease from early- to late-stage. Its growing late-stage oncology pipeline comprises complementary treatment approaches spanning immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies. BioNTech has partnered with multiple global and specialized pharmaceutical collaborators leveraging complementary expertise and resources to accelerate innovation and drive progress, including Bristol Myers Squibb, Duality Biologics, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, and Pfizer.

For more information, please visit www.BioNTech.com.

BioNTech Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the Company’s intent to repurchase, from time to time, the Company’s ADSs. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the

1

negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

The forward-looking statements in this press release are based on BioNTech’s current expectations and beliefs of future events and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech’s control, and which could cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: changes in the market price of the Company’s ADSs, general market conditions and applicable securities laws.

You should review the risks and uncertainties described under the heading “Risk Factors” in BioNTech’s Report on Form 6-K for the period ended March 31, 2026, and in subsequent filings made by BioNTech with the SEC, which are available on the SEC’s website at www.sec.gov. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. 

CONTACTS

Investor Relations

Douglas Maffei, PhD

Investors@biontech.de

Media Relations

Jasmina Alatovic

Media@biontech.de

2

FAQ

What did BioNTech (BNTX) announce regarding its share repurchase program?

BioNTech authorized a new share repurchase program for American Depositary Shares with an aggregate amount of up to $1.0 billion. The company intends to buy back ADSs over time to enhance capital efficiency and support long-term value creation while maintaining financial flexibility.

How long will BioNTech’s new $1.0 billion ADS buyback program last?

The share repurchase program may run until and including May 6, 2027. During this period, BioNTech may repurchase ADSs from time to time, depending on market conditions, focusing on price-efficient purchases to support prudent deployment of capital.

How does BioNTech plan to fund its $1.0 billion ADS repurchase program?

BioNTech expects to fund the new share repurchase program using its existing cash resources. This approach highlights the company’s strong financial position and allows it to return capital to shareholders while continuing to support its pipeline and strategic objectives.

What does BioNTech intend to do with the repurchased ADSs under the program?

BioNTech expects to use the repurchased ADSs to satisfy obligations in the ordinary course of business. This can include meeting commitments such as share-based compensation while aligning capital allocation with its broader long-term value creation goals.

Under which rules is BioNTech’s ADS repurchase program structured?

The program is designed to operate within the safe harbor of Rule 10b-18 and the affirmative defense of Rule 10b5-1 under the Exchange Act. These frameworks provide guidelines for orderly repurchases and pre-arranged trading plans.

What strategic objective does BioNTech link to its new share buyback program?

BioNTech states that the program is designed to enhance capital efficiency and support long-term value creation while maintaining flexibility alongside its objective to become a multi-product company by 2030, reflecting confidence in its growth strategy.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 11.7 KB